1 / 12

TAXUS WOMAN

TAXUS WOMAN. A Pooled Analysis of Outcomes with Paclitaxel-eluting Stents in Women and Men Simon Corbett Interventional Fellow St Mary’s Hospital. Background (1).

meryl
Download Presentation

TAXUS WOMAN

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TAXUS WOMAN A Pooled Analysis of Outcomes with Paclitaxel-eluting Stents in Women and Men Simon Corbett Interventional Fellow St Mary’s Hospital

  2. Background (1) • Previous trial and registry data have consistently shown worse outcomes in women compared to men undergoing coronary revascularisation • This is usually attributed to an adverse risk profile in women – they tend to be older, smaller and have more diabetes, hypertension and heart failure

  3. Background (2) • The efficacy of drug-eluting stents in reducing clinical restenosis across a wide range of lesion subsets is well-established • However, the efficacy of DES in women is assumed, not proven

  4. Aim of this Study • To assess the safety and efficacy of the paclitaxel-eluting TaxusTM stent in women

  5. Methodology • Pooled analysis of the Results from the TAXUS II, IV, V and VI randomized, controlled trials

  6. The TAXUSTM Trial Program

  7. Results • Between June 2001 and March 2004, 3445 patients were enrolled into the TAXUS II, IV, V and VI trials • Women comprised 27.7% (955 patients) • Stents received: Taxus 480, 475 bare metal • Men comprised 72.3% (2490 patients) • Stents received: Taxus 1238, 1252 bare metal • Follow-up is complete to 3 years for TAXUS II and IV, 2 years for TAXUS VI and 1 year for TAXUS V

  8. Baseline Patient Characteristics *P-value=non-significant for all comparisons between the Taxus and Control groups in women and men (data not shown)

  9. Baseline Lesion and Procedural Characteristics *P-value=non-significant for all comparisons between the Taxus and Control groups in women and men (data not shown)

  10. Clinical Outcomes at 30 days

  11. Clinical Outcomes at 1 year

  12. Conclusions • The Taxus stent is as effective at reducing repeat revascularization in women as men • The Taxus stent is safe in women • Long-term clinical outcomes in women and men treated in these contemporary PCI studies are equivalent despite the adverse risk profile of women at baseline • Women treated with the Taxus stent have a lower rate of late stent thrombosis than men

More Related